국내 양돈장에서 돼지글래셔병을 동반한 PMWS에 대한 M+ parapac®의 방어효과

The purpose of this study was to evaluate the efficacy and cross-protection of serovar 12 against serovar 4 or 5 of H parasuis with M+Parapac®. A total of 141 piglets from 2(A and B) farms were used and divided into experimental group and control group in each farm. Farm A has been detected H parasuis serovar 12, whereas farm B has been detected H parasuis serovar 4 or 5 from post-weaned pigs with PMWS. The piglets were vaccinated intramuscularly with 2.0ml of M+Parapac® in experimental group or normal saline in control group at 1 week of age. A same booster dose was given at 3 weeks of age. In order to value the antibody titer to H parasuis using by tube agglutination test, blood samples were collected from piglets at the aged of 1 week, 6 and 14 weeks. In experimental group and control group, the average antibody titers were 32.5±21.0, 114.5±34.0, 98.1±55.4 and 32.9±18.6, 25.8±36.9, 746.7±1,215.8 at the aged of 1 week, 6 and 14 weeks, respectively. The cumulative clinical sign indexes by standard guideline of Schering-Plough Animal Health Corp were 486 and 1,069, respectively. The average daily gains and feed conversion rates were 0.553±0.016kg and 0.492±0.004kg, and 1.99 and 2.24, respectively. The average gross lesion scores were 1.0±0.8 and 1.9±0.6, respectively. According to these results, the M+ Parapac® containing H parasuis serovar 12 may be induce circulating antibodies that cross-react with serovar 4 or 5 and have a protection of PMWS with H parasuis.